OneMedRadio: Immune Pharmaceuticals CEO and Epicept Corporation CEO Discuss Merger

Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.

Read more »

Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.

Read more »

Bulls, Bears: The State of Cancer Immunotherapy in the Public Markets

This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Read more »

BIOTECH 2012: Panel of CEOs — Lather, Rinse, Repeat

Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stimulating conversation and a new perspective on the industry.

Read more »

CEVEC Pharmaceuticals GmbH Raises € 2.8MM in Series C Financing

CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund.

Read more »

Dendreon: Anticancer Immunotherapy, Reimbursement, and New Promises

This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Read more »

OneMedRadio: Healthtech Conference 2012 — What to Watch For

HealthTech Conference 2012, on October 26th in San Francisco, is a single day summit covering the most important issues in this burgeoning sector. OneMedRadio spoke with Anne Degheest, Managing Director and Founder of HealthTech Capital, about conference programming, and the unique investment opportunity in the sector.

Read more »

Special Report: Monitoring the Safety of Post-Market Medical Devices

Tatyana Chorny answered a series of questions written by marcus evans before the forthcoming Medical Device Safety Monitoring and Reporting Conference, January 17-18, 2013 in Las Vegas, NV. Tatyana shares her thoughts on timely reporting and regulatory compliance.

Read more »

Press Release: Colby Pharmaceuticals Acquires Othera Pharmaceuticals

Colby Pharmaceutical Company (Colby), a privately held San Jose, CA based biopharmaceutical company, announced that it has acquired Othera Pharmaceuticals Inc. (Othera) of Conshohocken, PA.

Read more »

Bulls, Bears: Sepsis and Anti-Infectives in the Public Markets

The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.

Read more »